Anna V Medem1, Hanna M Seidling1, Hans-Georg Eichler2, Jens Kaltschmidt1, Michael Metzner1, Carina M Hubert1, David Czock1, Walter E Haefeli3. 1. Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. 2. European Medicines Agency, 30 Churchill Place, Canary Wharf, London, E14 5EU, UK. 3. Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. walter.emil.haefeli@med.uni-heidelberg.de.
Abstract
PURPOSE: Electronic clinical decision support systems (CDSS) require drug information that can be processed by computers. The goal of this project was to determine and evaluate a compilation of variables that comprehensively capture the information contained in the summary of product characteristic (SmPC) and unequivocally describe the drug, its dosage options, and clinical pharmacokinetics. METHODS: An expert panel defined and structured a set of variables and drafted a guideline to extract and enter information on dosage and clinical pharmacokinetics from textual SmPCs as published by the European Medicines Agency (EMA). The set of variables was iteratively revised and evaluated by data extraction and variable allocation of roughly 7% of all centrally approved drugs. RESULTS: The information contained in the SmPC was allocated to three information clusters consisting of 260 variables. The cluster "drug characterization" specifies the nature of the drug. The cluster "dosage" provides information on approved drug dosages and defines corresponding specific conditions. The cluster "clinical pharmacokinetics" includes pharmacokinetic parameters of relevance for dosing in clinical practice. A first evaluation demonstrated that, despite the complexity of the current free text SmPCs, dosage and pharmacokinetic information can be reliably extracted from the SmPCs and comprehensively described by a limited set of variables. CONCLUSION: By proposing a compilation of variables well describing drug dosage and clinical pharmacokinetics, the project represents a step forward towards the development of a comprehensive database system serving as information source for sophisticated CDSS.
PURPOSE: Electronic clinical decision support systems (CDSS) require drug information that can be processed by computers. The goal of this project was to determine and evaluate a compilation of variables that comprehensively capture the information contained in the summary of product characteristic (SmPC) and unequivocally describe the drug, its dosage options, and clinical pharmacokinetics. METHODS: An expert panel defined and structured a set of variables and drafted a guideline to extract and enter information on dosage and clinical pharmacokinetics from textual SmPCs as published by the European Medicines Agency (EMA). The set of variables was iteratively revised and evaluated by data extraction and variable allocation of roughly 7% of all centrally approved drugs. RESULTS: The information contained in the SmPC was allocated to three information clusters consisting of 260 variables. The cluster "drug characterization" specifies the nature of the drug. The cluster "dosage" provides information on approved drug dosages and defines corresponding specific conditions. The cluster "clinical pharmacokinetics" includes pharmacokinetic parameters of relevance for dosing in clinical practice. A first evaluation demonstrated that, despite the complexity of the current free text SmPCs, dosage and pharmacokinetic information can be reliably extracted from the SmPCs and comprehensively described by a limited set of variables. CONCLUSION: By proposing a compilation of variables well describing drug dosage and clinical pharmacokinetics, the project represents a step forward towards the development of a comprehensive database system serving as information source for sophisticated CDSS.
Keywords:
Clinical decision support system (CDSS); Dosage; Drug label; Electronic summary of product characteristics (e-SmPC); Pharmacokinetics; Summary of product characteristics (SmPC)
Authors: Adam Wright; Joshua Feblowitz; Shobha Phansalkar; Jialin Liu; Allison Wilcox; Carol A Keohane; Diane L Seger; Meryl Bloomrosen; Gilad J Kuperman; David W Bates Journal: Am J Health Syst Pharm Date: 2012-02-01 Impact factor: 2.637
Authors: Simon Maxwell; Hans-Georg Eichler; Anna Bucsics; Walter E Haefeli; Lars L Gustafsson Journal: Br J Clin Pharmacol Date: 2012-01 Impact factor: 4.335
Authors: Olga R Brook; Janneth Romero; Alexander Brook; Jonathan B Kruskal; Chun S Yam; Deborah Levine Journal: Radiology Date: 2014-09-01 Impact factor: 11.105
Authors: Kay Seden; Jamie J Kirkham; Tom Kennedy; Michael Lloyd; Sally James; Aine McManus; Andrew Ritchings; Jennifer Simpson; Dave Thornton; Andrea Gill; Carolyn Coleman; Bethan Thorpe; Saye H Khoo Journal: BMJ Open Date: 2013-01-09 Impact factor: 2.692